Latest news with #CVSHealthCorporation
Yahoo
4 days ago
- Business
- Yahoo
CVS Health Corporation (CVS): Jim Cramer Says You Don't Want Them Buying The Wrong Robots
We recently published a list of . In this article, we are going to take a look at where CVS Health Corporation (NYSE:CVS) stands against other stocks that Jim Cramer discusses. CVS Health Corporation (NYSE:CVS) is one of the largest pharmaceutical retailers in America. The firm's shares have gained 44% year-to-date due to weakness at the firm's primary rival Walgreens. Cramer's previous remarks about CVS Health Corporation (NYSE:CVS) have praised the firm's CEO and his turnaround efforts. The shares gained 4% in May after the firm raised its 2025 profit forecast to a midpoint of $6.10 per share from an earlier $5.87 per share. CVS Health Corporation (NYSE:CVS)'s turnaround efforts which have seen the firm appoint a new CEO and exit its Obamacare direct sales business have contributed to the strong 2025 share price performance. In his recent comments about CVS Health Corporation (NYSE:CVS), Cramer wondered what would happen if the firm automated its pharmacies through robots: 'I mean one of the things that is really meant to be changing here is healthcare. And you don't want, uh, CVS, for instance, if they were to buy a robot, you don't want them saying, do remember that scene, It's a Wonderful Life, where the pharmacist gave them the wrong prescription? You don't want that. You don't want It's a Wonderful Life, to be your life.' In his previous comments, the CNBC host praised the firm's management. Here's what he said: 'Now we've got some healthcare, some issues to talk about on Thursday, that's right, and these are anything but common steady healthcare companies…. There's CVS, which is under new management, put up some really good numbers, and it's just, that's in health insurance, but also it's core drugstore business, which they've closed, all the under performers… As for CVS, the health insurers have taken it on the chin of late. UnitedHealth and Centene both missed expectations. I bet Aetna sticks it.' A row of shelves in a retail pharmacy, demonstrating the variety of drugs and over-the-counter products. Overall, CVS ranks 11th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of CVS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. This article is originally published at .
Yahoo
5 days ago
- Business
- Yahoo
Online Pharmacy Market Set to Reach USD 472.09 Billion by 2032, Driven by Digital Healthcare Expansion and Mobile Accessibility
SNS Insider Highlights Explosive Growth of the U.S. Online Pharmacy Market—Valued at USD 47.41 Billion in 2024—As the Country Secures Dominance in Digital Medication Delivery with Over 41% Global Market Share Austin, June 05, 2025 (GLOBE NEWSWIRE) -- Online Pharmacy Market Size & Growth Analysis: According to SNS Insider, the global Online Pharmacy Market was valued at USD 131.77 billion in 2024 and is projected to reach USD 472.09 billion by 2032, expanding at a CAGR of 17.35% over the forecast period (2025–2032). The market is experiencing a surge as consumers turn to digital platforms for medication access, especially amid rising internet and smartphone penetration. The growing preference for convenient, home-delivered medicines, combined with the integration of telehealth services, has transformed how consumers engage with pharmacies. Governments around the world are embracing digital health initiatives, while private players deploy AI and machine learning to personalize healthcare experiences, boosting adoption of online pharmacy a Sample Report of Online Pharmacy Market@ U.S. Leads North American Online Pharmacy Market The U.S. online pharmacy market was estimated at USD 47.41 billion in 2024 and is expected to reach USD 165.16 billion by 2032, at a CAGR of 16.94% during the forecast period of 2025-2032. The North America region of the online pharmacy market is led by the U.S., highly internet penetration, good smartphone penetration, and an existing digital healthcare infrastructure, which has consolidated this supremacy over other markets. Increased demand for medications delivered at home and the integration of telehealth services led to the rapid transfer of existing pharmaceutical practices to online stores in the country. Major Players Analysis Listed in this Report are: CVS Health Corporation Walgreens Boots Alliance Amazon Pharmacy Alibaba Health Information Technology Netmeds Tata 1mg PharmEasy Rite Aid Corporation Capsule Pharmacy Apollo Pharmacy other players Online Pharmacy Market Report Scope Report Attributes Details Market Size in 2024 US$ 131.77 billion Market Size by 2032 US$ 472.09 billion CAGR CAGR of 17.35% From 2025 to 2032 Base Year 2024 Forecast Period 2025-2032 Historical Data 2021-2023 Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Segment Analysis: By Product Type, the Health, Wellness, and Nutrition Segment to Register Fastest Growth The Health, Wellness, and Nutrition segment is estimated to record the fastest CAGR over the forecast years, owing to increasing emphasis on preventive healthcare and lifestyle management in the global online pharmacy market. With the rising awareness about immunity, mental well-being, and health, consumers are increasingly purchasing vitamins, dietary supplements, herbal, and fitness-related products through the digital medium. By Platform, Mobile Users Segment Dominates the Online Pharmacy Market By 2024, the online pharmacy market dominated by the mobile user segment with a 91.24% market share, as the increasing use of smartphones and mobile apps facilitates access to healthcare services. The ability to check for medications, receive orders, and trace orders via mobile devices has dramatically improved user participation. Furthermore, mobile platforms also accommodate e-prescriptions, health consumption rate, and customized notifications, so they encourage reuse. By Drug Type, the Prescription Medicines Segment Dominates the Online Pharmacy Market with an 83.14% Market share. The prescription medicines segment held the largest market share in the online pharmacy market in 2024, owing to high requirements for chronic disease management drugs (e.g., for diabetes, hypertension, and cardiovascular disease) and medicines in general. Online pharmacies provide more access and convenience for patients who need frequent refills of their prescription medications. Integration with telemedicine services and e-prescriptions adds to this trend, offering stress-free digital consultations and instant orders. Need Any Customization Research on Online Pharmacy Market, Enquire Now@ Regional Trends: North America Dominates the Online Pharmacy Market, Asia Pacific Expected to Register Fastest Growth North America dominated the online pharmacy market with a 41.2% market share in 2024, owing to a well-established healthcare infrastructure, high internet penetration, and adoption of digital health technologies. Regional growth is further strengthened by the high concentration of major market players, favorable insurance coverage, and an increase in demand for prescription medications via home delivery. Asia Pacific will have the fastest growth in the online pharmacy market with an 18.48% CAGR during the forecast period, due to rising smartphone adoption, developing internet infrastructure, and increasing awareness of health in developing countries. The need for easy and low-priced medicines is driven by rapid urbanization, a growing middle-class population, and the rise of e-commerce platforms. Coupled with investments in the infrastructure for online pharmacies, government initiatives promoting digital health are paving the way for countries such as India and China to become important hotspots for digital pharmaceutical services. Online Pharmacy Market Segmentation By Product Type Medication & Treatments Health, Wellness, and Nutrition Personal Care and Essentials Others By Platform Mobile Users Desktop Users By Drug Type OTC Medicines Prescription Medicines Buy a Single-User PDF of Online Pharmacy Market Analysis & Outlook Report 2024-2032@ Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Online Pharmacy Usage Penetration, by Region (2024) 5.2 Prescription Fulfillment Trends, by Drug Type and Region (2024) 5.3 Consumer Spending on Online Pharmacy Purchases, by Region and Category (2024) 5.4 Telepharmacy and Virtual Consultation Utilization, by Region (2024) 6. Competitive Landscape 7. Online Pharmacy Market by Product Type 8. Online Pharmacy Market by Platform 9. Online Pharmacy Market by Drug Type 10. Regional Analysis 11. Company Profiles 12. Use Cases and Best Practices 13. Conclusion About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@
Yahoo
19-05-2025
- Business
- Yahoo
Here's Why CVS Health Corp. (CVS) Traded Higher in Q1
Hotchkis & Wiley, an investment management company, released its 'Hotchkis & Wiley Mid-Cap Value Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The Hotchkis & Wiley Mid-Cap Value Fund returned -5.63% in the first quarter, underperforming the Russell Midcap Value Index's -2.11% return. US mid-cap stocks surged post-Presidential elections due to potential benefits of deregulation, lower corporate taxes, and accelerated growth. However, Q1 2025 saw a decline due to tariffs, high inflation, and weak macroeconomic factors, causing the Russell Midcap Index to decline by -3.4% and the Russell Midcap Value Index by -2.1% vs. a decline of -7.1% for the Russell Midcap Growth Index. For more information on the fund's best picks in 2025, please check its top five holdings. In its first-quarter 2025 investor letter, Hotchkis & Wiley Mid-Cap Value Fund highlighted stocks such as CVS Health Corporation (NYSE:CVS). CVS Health Corporation (NYSE:CVS) is a US-based health solutions provider. The one-month return of CVS Health Corporation (NYSE:CVS) was -4.05%, and its shares gained 8.94% of their value over the last 52 weeks. On May 16, 2025, CVS Health Corporation (NYSE:CVS) stock closed at $62.53 per share with a market capitalization of $79.1 billion. Hotchkis & Wiley Mid-Cap Value Fund stated the following regarding CVS Health Corporation (NYSE:CVS) in its Q1 2025 investor letter: "CVS Health Corporation (NYSE:CVS) is a diversified healthcare company operating as a Pharmacy Benefits Manager (PBM), health insurer, and retail stores and pharmacies. In January, CVS and other health insurers with large Medicare Advantage plans rose after the Centers for Medicare & Medicaid Services (CMS) published better-than-expected reimbursement rates for 2026. CVS maintained that momentum in February by reporting expected fourth[1]quarter results. It then reported decent quarterly results. The PBM segment and physical stores were in line with expectations. However, Aetna incurred losses across multiple lines of business, driven by Medicare Advantage and the Exchanges. Despite this, the losses in the health insurance segment were less severe than anticipated, leading to a positive market reaction." A row of shelves in a retail pharmacy, demonstrating the variety of drugs and over-the-counter products. CVS Health Corporation (NYSE:CVS) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 74 hedge fund portfolios held CVS Health Corporation (NYSE:CVS) at the end of the fourth quarter, compared to 63 in the third quarter. In the first quarter of 2025, CVS Health Corporation (NYSE:CVS) reported revenue of $94.59 billion, representing 7% year-over-year growth. While we acknowledge the potential of CVS Health Corporation (NYSE:CVS) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered CVS Health Corporation (NYSE:CVS) and shared the list of best unstoppable stocks that pay dividends. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
18-05-2025
- Business
- Yahoo
Rite Aid to Sell Majority of U.S. Pharmacy Operations to Rivals, Including CVS Health Corporation (CVS)
Rite Aid has sold the pharmacy operations of more than 1,000 of its U.S. stores to major competitors, including CVS Health Corporation (NYSE:CVS), Walgreens, Albertsons, and Kroger, as part of its ongoing Chapter 11 bankruptcy process. CVS Health Corporation (NYSE:CVS) emerged as the largest buyer, acquiring prescription records from over 600 Rite Aid locations across 15 states, and agreeing to purchase 64 physical stores in Idaho, Oregon, and Washington. The deals are pending approval from the bankruptcy court. Despite the asset sales, Rite Aid stated that its stores remain open and customers can continue using its pharmacy services without disruption. CEO Matt Schroeder said that the agreements will allow pharmacy customers to transition smoothly while also helping retain some employees. He emphasized that the move ensures customers will continue receiving the pharmacy care and services they need without any disruptions. The added stores would help CVS Health Corporation (NYSE:CVS) expand its footprint in an area where it currently has fewer locations relative to the population compared to other parts of the country. This offers a strategic expansion opportunity for the company. Alongside strengthening its foothold in the retail pharmacy market, CVS is also drawing investor interest thanks to its consistent dividend payments. The company has maintained consistent payments since 1997 and currently offers a quarterly dividend of $0.665 per share. As of May 18, the stock has a dividend yield of 4.25%. While we acknowledge the potential of CVS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CVS and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and Disclosure. None.
Yahoo
14-05-2025
- Business
- Yahoo
Why CVS Health Corporation (CVS) Declined on Tuesday
We recently published an article titled . In this article, we are going to take a look at where CVS Health Corporation (NYSE:CVS) stands against the other stocks. Wall Street's main indices finished mixed on Tuesday, as investors digested the country's latest inflation figures, which came out lower than expected. On Tuesday, the Labor Department reported that the Consumer Price Index for April rose by only 0.2 percent last month, bringing the annual inflation rate to 2.3 percent, versus the 2.4 percent in March. It was the lowest annual rate since February 2021. Only the S&P 500 and the tech-heavy Nasdaq registered gains among all major indices, up by 0.72 percent and 1.61 percent, respectively. The Dow Jones, on the other hand, was down by 0.64 percent. Beyond the main indices, 10 firms lagged in performance amid negative news, sparking sell-offs. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. A row of shelves in a retail pharmacy, demonstrating the variety of drugs and over-the-counter products. CVS Health Corporation (NYSE:CVS) extended its losing streak for a third straight day on Tuesday, dropping 6.65 percent to close at $60.50 apiece as investor sentiment was dampened by President Donald Trump's executive order to lower the prices of medicines. The news sparked fears among investors over the impact of the new order on the profits and margins of drugmakers and retailers, including CVS Health Corporation (NYSE:CVS). Further weighing down on sentiment was a lawsuit filed by four state attorneys general against the company, claiming that CVS Health Corporation (NYSE:CVS) and its pharmacies allegedly submitted 'false and fraudulent' claims to state Medicaid programs. According to attorneys general from Connecticut, Indiana, Oklahoma, and Massachusetts, CVS Health Corporation (NYSE:CVS) has not submitted usual and customary prices available to other payers on prescription drug claims to Medicaid since 2016. CVS has yet to comment on the allegations. Overall CVS ranks 9th on our list of Tuesday's worst performers. While we acknowledge the potential of CVS as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than CVS but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
